Jupiter Neurosciences Announces Pricing of $2 Million Registered Direct Offering
Jupiter Neurosciences has announced the pricing of a $2.0 million registered direct offering. This offering aims to raise capital for the company's operations.
Results for "Jupiter Neurosciences"
4 stories found
Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million
Jupiter Neurosciences has signed a license agreement for ALA-002, potentially valued at up to $100 million. This deal represents a significant development for the company's pharmaceutical pipeline and financial outlook.
Jupiter Neurosciences Announces 1-for-75 Reverse Stock Split
Jupiter Neurosciences has declared a 1-for-75 reverse stock split.
Jupiter Neurosciences CEO and President Discuss Psychedelic Therapy and M&A
Jupiter Neurosciences CEO Christer Rosén and President Alison Silva participated in a fireside chat, discussing the intersection of psychedelic therapy and mergers and acquisitions.